- Visibility 638 Views
- Downloads 716 Downloads
- Permissions
- DOI 10.18231/j.ijogr.v.12.i.3.10
-
CrossMark
Study of efficacy of selective estrogen receptor modulator: Ormeloxifene in the management of heavy menstrual bleeding in perimenopausal patients: A prospective interventional study
- Author Details:
-
Nitin Naresh Kulkarni
-
Priyanka Lalitkumar Agrawal
-
Aakanksha Bhagirathrao Deshmukh
-
Aakruti Atul Ganla *
Nitin Naresh Kulkarni
Background: Menorrhagia is a common complaint of about 10-33% of women in perimenopausal period. Ormeloxifene is a third – generation selective estrogen receptor modulator (SERM) highly efficacious in the management of Heavy Menstrual Bleeding, but not commonly used at present.
Aim & Objective: To determine the therapeutic efficacy of SERM in management of HMB.
Materials and Methods: An institution based prospective study was conducted on 150 patients in the age group of 35-45 years who were treated with 60mg ormeloxifene twice a week for the first 3 months and once weekly for the next 3 months. The outcome was assessed based on menstrual blood loss in terms of PABC score, endometrial thickness and hemoglobin concentration.
Results: The treatment effects of ormeloxifene, in patients of Heavy Menstrual bleeding was found * PBAC score has decreased to 95 ± 28.35 in 6 months from the basal value of 244.15 ± 35.04. *endometrial thickness (in mm) has decreased to 6.70 ± 1.22 at 6 months, from the basal value of 9.57± 1.15 (mm). Haemoglobin levels have increased to 9.57 ± 0.84 at 6 months from the basal value of 7.52 ± 0.75(gm/dl).
Conclusion: Ormeloxifene is very safe, cost-effective and with manageable side effects and hence, can be used as the drug of choice in patients with HMB.
References
- Kocaoz S, Cirpan R, Degirmencioglu AZ. The prevalence and impacts heavy menstrual bleeding on anemia, fatigue and quality of life in women of reproductive age. Pak J Med Sci. 2019;35(2):365–
- ACOG Committee on Practice Bulletins—Gynecology. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72(3):263–71.
- Shrivastava N, Rani R. Efficacy and safety of ormeloxifene, a selective estrogen receptor modulator in management of dysfunctional uterine bleeding in perimenopausal patients: a prospective interventional study. Int J Reprod Contracept Obstet Gynecol. 2023;12(12):3474–8.
- Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990;30(4):353–6.
- Nandhini GM, Hiremath PB, Banu AS. A study of efficacy of ormeloxifene in abnormal uterine bleeding of ovulatory disorders. Int J Reprod Contracept Obstet Gynecol. 2022;11(4):1230–5.
- Pati T, Chanania K, Marandi S, Hansa J. Ormeloxifene – Looking beyond contraception. J Midlife Health. 2017;8(1):17–20.
- Mani A, Sharma K, Kumar A, Talukdar RK. Selective estrogen receptor modulator: efficacy in abnormal uterine bleeding in perimenopausal women. Int J Reprod Contracept Obstet Gynecol. 2019;8(4):1495–9.
- Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987;34(1):99–110.
- Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102(5):401–6.
- Khan SA, Manzoor M, Abdullah A, Banoo A. Efficacy and safety of ormeloxifene in the management of dysfunction uterine bleeding. J Dent Med Sci. 2014;13(6):39–42.
- Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(11):2534–6.
- Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res. 2009;35(4):746–52.
- Dhananjay BS, Nanda SK. The role of sevista in the management of dysfunctional uterine bleeding. J Clin Diagn Res. 2012;7(1):132–4.
- Shravage J, Mekhala D, Bellad MB, Ganachari MS, Dhumale HA. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: a double blind randomized controlled trial. J South Asian Fed Obstet Gynaecol. 2011;3(1):21–4
- Chhatrala JJ, Chawada R, Saini HB. Comparative study between ormeloxifene and oral contraceptive pills in the treatment of dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2017;4(2):366–9.
- Biswas SC, Saha SK, Bag TS, Ghosh Roy SC, Roy AC, Kabiraj SP, et al. Ormeloxifene a selective estrogen receptor modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynaecol Ind. 2004;54(1):56–9.